Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma

• Published in: International journal of hematology Vol. 111; no. 3; pp. 475 - 479
• Main Authors: Ogasawara, Reiki, Hashimoto, Daigo, Sugita, Junichi, Yamawaki, Fumihiko, Naka, Tomoaki, Mitsuhashi, Tomoko, Takahashi, Shuichiro, Miyashita, Naohiro, Okada, Kohei, Onozawa, Masahiro, Matsuno, Yoshihiro, Teshima, Takanori
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.03.2020; Springer Nature B.V
• Subjects: Adult; Binding; Biomarkers; Case Report; Flow Cytometry; Forecasting; Graft-versus-host reaction; Health risks; Hematology; Hematopoietic stem cells; Hodgkin Disease - drug therapy; Hodgkin Disease - genetics; Hodgkin's lymphoma; Humans; Immunotherapy; Lymphocytes; Lymphocytes T; Lymphoma; Male; Masks; Medicine; Medicine & Public Health; Monoclonal antibodies; Neoplasm Recurrence, Local; Nivolumab - administration & dosage; Nivolumab - metabolism; Oncology; PD-1 protein; Programmed Cell Death 1 Receptor - metabolism; Protein Binding; Restoration; Stem cell transplantation; Stem cells; T-Lymphocytes - metabolism; Targeted cancer therapy; Transplantation; Tumors; Young Adult; Checkpoint inhibitor; Graft-versus-host disease; Allogeneic stem cell transplantation; PD-1; Hodgkin lymphoma
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-019-02737-4

Nivolumab is effective in the treatment of classical Hodgkin lymphoma that relapsed after allogeneic hematopoietic stem cell transplantation (SCT) with the risk of graft-versus-host disease; however, the optimal time and dose of nivolumab administration remain to be investigated. Nivolumab binding to PD-1 masks flowcytometric detection of PD-1 by the anti-PD-1 monoclonal antibody EH12.1. Using this method, we monitored nivolumab binding on T cells after nivolumab treatment in a patient with classical Hodgkin lymphoma relapsed after allogeneic SCT. Nivolumab was effective while prolonged nivolumab binding was evident, but restoration of PD-1 staining predicted tumor relapse. Flowcytometric monitoring of nivolumab binding on T cells could be a promising biomarker for predicting tumor relapse and determining the timing of nivolumab administration.